Visual Outcomes With a Trifocal IOL in Subjects With Open-angle Glaucoma
NCT ID: NCT04619654
Last Updated: 2022-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
25 participants
INTERVENTIONAL
2021-02-01
2022-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Interventional Cohort Study to Evaluate the Efficacy and Safety of the AquaLumen, a Novel Filtration Procedure for the Treatment of Open Angle Glaucoma
NCT06809647
Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery
NCT01455467
Study of OMNI Surgical System and iStent for Eyes With OAG (Trident)
NCT04658095
Long-Term IOP Fluctuation and VF Progression After Triple Procedure
NCT00428740
Comparative Effectiveness of Treatment Strategies for Primary Open-Angle Glaucoma
NCT01645319
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cataract Surgery with concurrent MIGS
Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold
Cataract surgery with implantation of the PanOptix IOL combined with minimally invasive glaucoma surgery utilizing the Hydrus Microstent
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold
Cataract surgery with implantation of the PanOptix IOL combined with minimally invasive glaucoma surgery utilizing the Hydrus Microstent
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. A visually significant cataract
3. Diagnosis of mild OAG
* Vertical C/D ratio of less than or equal to 0.8
* VF characteristics consistent with glaucoma with mean deviation not worse than -6.00 dB and without fixation threatening scotoma AND/OR with nerve abnormalities consistent with glaucoma (rim notching, rim thinning, disc hemorrhage, nerve fiber layer loss)
* Medicated IOP 25 of less than or equal to mmHg on 1-3 medications
* If treatment naïve (before glaucoma treatment) IOP between 21 and 35 mmHg
4. Glaucoma must be judged as stable by investigator based on review of subject medical records
* Stable VF at least 1 year prior to surgery
* Stable nerve fiber layer at least 1 year prior to surgery
* IOP stable on current medication regimen at least 3 months prior to surgery
5. Shaffer grade of greater than III in all quadrants
6. Potential of good best corrected visual acuity at distance in the investigator's judgement of at least 0.1 logMAR (20/25) postoperatively
7. Able and willing to comply with follow up visits
8. Understands and signs the informed consent
Exclusion Criteria
2. Prior laser trabeculoplasty within 90 days of surgery
3. Pseudoexfoliative, angle closure, uveitic, congenital, traumatic, angle recession, or neovascular glaucoma.
4. Moderate glaucoma with VF mean deviation between -6.00 dB and -12.00 dB
5. Severe and/or progressive glaucoma defined as
* VF mean deviation worse than -12.00 dB
* Consistent worsening of visual field on review of subject medical records
* Consistent and progressive thinning of nerve fiber layer on review of subject medical records
* Uncontrolled IOP on maximum glaucoma medications
* Historically poor IOP control with medical therapy
* Severe focal notching of the optic nerve rim
* Expectation for future need of incisional glaucoma surgery
6. Ocular pathology or other medical condition which, in the investigator's judgment places the subject at increased risk of complications or significant vision loss during study period.
7. Ocular pathology that in the investigator's judgment may impact visual acuity postoperatively, i.e. significant ocular surface disease, corneal scarring, blepharitis, epiretinal membrane, macular degeneration, history of significant ocular trauma with sequela, etc.
8. Pregnant or breastfeeding women
9. Prior refractive surgery e.g. LASIK, RK, PRK, etc.
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Vold Vision P.L.L.C
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vold Vision P.L.L.C.
Fayetteville, Arkansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PanOptix Trifocal 001, Rev A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.